Mini Review
Volume 9 Issue 1 - 2021
Prescribing Ivermectin in COVID-19: The Reality of a Panacea
Franklin Rouselbel Correa Prieto*
Emergency Department, Hospital Nacional de la Policía Luis Nicasio Sáenz, Second Specialty Program, School of Medicine, San Martín de Porres University, Perú
*Corresponding Author: Franklin Rouselbel Correa Prieto, Emergency Department, Hospital Nacional de la Policía Luis Nicasio Sáenz, Second Specialty Program, School of Medicine, San Martín de Porres University, Perú.
Received: November 01, 2020; Published: December 11, 2020




Abstract

The coronavirus disease 2019 (COVID-19), almost a year after the first case report, present in 190 countries of the world, with 45,683,708 infected and 1,190,516 deaths at the moment. The disease is classified into four spectra: mild, moderate, severe, and critical spectrum; based on its clinical characteristics and lung parenchyma affection verified by tomography. To date, there are no drugs designed for a specific treatment of severe acute respiratory syndrome caused by the new corona virus (SARS-CoV2), or vaccines that have been shown to be effective in preventing COVID-19. However, in a race against time, clinical trials of many drugs are ongoing. While cohort studies report consistent efficacy results for ivermectin; only the results of the large randomized clinical trials, with rigorous methodology that are being carried out or recruited, will be able to definitively establish how useful ivermectin is to treat COVID-19 or for its prophylaxis if applicable, alone or in combination. In the coming months, we must await the reports of the results of these trials and determine the antiviral viability of this drug, against SARS-CoV-2 and other viral diseases. Medical management must be focused responsibly, avoiding the unnecessary administration of drugs. The care of the patient with COVID-19 in any of the spectra of the disease should not be based on personal experience as a clinician, or on consensus; but rather in the physiological principles, in the natural history of the disease, in the pathophysiological mechanisms and in evidence-based medicine to be able to make the corresponding clinical decisions, honoring the words “primum non nocere” in each patient.

Keywords: Covid-19; Severe Acute Respiratory Syndrome Coronavirus 2; Covid-19 Drug Treatment; Ivermectin; Evidence-Based Medicine; Evidence-Based Emergency Medicine

References

  1. Khan Z., et al. “COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts”. Le Pharmacien Hospitalier et Clinicien (2020).
  2. Dong E., et al. “An interactive web-based dashboard to track COVID-19 in real time”. The Lancet Infectious Diseases 5 (2020): 533-534.
  3. Coronavirus Disease (COVID-19) Situation Reports (2020).
  4. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
  5. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. The Lancet 10223 (2020): 507-513.
  6. Pan F., et al. “Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)”. Radiology3 (2020): 715-721.
  7. Yang X., et al. “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”. The Lancet Respiratory Medicine5 (2020): 475-481.
  8. Khan Z., et al. “COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts”. Le Pharmacien Hospitalier et Clinicien (2020).
  9. Verma H., et al. “Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19)”. Biomedical Journal (2019).
  10. Kaur S and Gupta V. “COVID-19 Vaccine: A comprehensive status report”. Virus Research 288 (2020): 198114.
  11. World Economic Forum. This Is How Much The Coronavirus Will Cost The World's Economy, According To The UN (2020).
  12. C Harrison. “Coronavirus puts drug repurposing on the fast track”. Nature Biotechnology 38 (2020): 379-381.
  13. Wagstaff K., et al. “Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus”. Biochemical Journal3 (2012): 851-856.
  14. González Canga A., et al. “The Pharmacokinetics and Interactions of Ivermectin in Humans-A Mini-review”. The AAPS Journal1 (2008): 42-46.
  15. World Health Organization. Model List Of Essential Medicines (2019).
  16. Varghese F., et al. “Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses”. Antiviral Research 126 (2016): 117-124.
  17. Kumar B Suresh., et al. “A wonder drug in the arsenal against COVID-19: medication evidence from ivermectin”. Journal of Advances in Medicine and Medical Research (2020): 30-37.
  18. Lv Changjie., et al. “Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus In vitro and vivo”. Antiviral Research 159 (2018): 55-62.
  19. King Cason R., et al. “Inhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin”. Journal of Virology18 (2020).
  20. Jans David A and Kylie M Wagstaff. “The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2?” Biochemical and Biophysical Research Communications (2020).
  21. Portmann-Baracco., et al. “Antiviral and anti-inflammatory properties of ivermectin and its potential use in Covid-19”. Archivos De Bronconeumologia (2020).
  22. Njoo FL., et al. “Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions”. The American Journal of Tropical Medicine and Hygiene 1 (1995): 94-99.
  23. Nguyen NL., et al. “Advantages of ivermectin at a single dose of 400 mcg/kg compared with 100 mcg/kg for community treatment of lymphatic filariasis in Polynesia”. Transactions of the Royal Society of Tropical Medicine and Hygiene 88 (1994): 461-464.
  24. Adelsberger Helmuth., et al. “Activation of rat recombinant α1β2γ2S GABAA receptor by the insecticide ivermectin”. European Journal of Pharmacology2-3 (2000): 163-170.
  25. Jans David A., et al. “Inhibitors of nuclear transport”. Current Opinion in Cell Biology 58 (2019): 50-60.
  26. Gupta Dhyuti., et al. “Ivermectin: potential candidate for the treatment of Covid 19”. Brazilian Journal of Infectious Diseases 4 (2020): 369-371.
  27. Formiga Fabio Rocha., et al. “Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 (2020).
  28. Schmith Virginia D., et al. “The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19”. Clinical Pharmacology and Therapeutics (2020).
  29. Aziz Asma B., et al. “Integrated control of COVID-19 in resource poor countries (2020).
  30. República del Perú. Ministerio de Salud. RM_270-2020-MINSA. República del Perú Ministerio de Salud (2020).
  31. India – Trial Site News [Internet] Ivermectin usage accelerates while the need for data is real: how about an ivermectin registry? (2020).
  32. Gobierno del Estado Plurinacional de Bolivia. Misterio de Salud. Resolución Ministerial No 259 del Gobierno del Estado Plurinacional de Bolivia Misterio de Salud (2020).
  33. Vora Agam., et al. “White paper on Ivermectin as a potential therapy for COVID-19”. Indian Journal of Tuberculosis3 (2020): 448-451.
  34. Prophylactic Ivermectin in COVID-19 Contacts - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials (2020).
  35. Rajter Juliana Cepelowicz., et al. “Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)”. Chest (2020).
Citation: Franklin Rouselbel Correa Prieto. “Prescribing Ivermectin in COVID-19: The Reality of a Panacea”. EC Pharmacology and Toxicology 9.1 (2021): 01-06.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk